Product logins

Find logins to all Clarivate products below.


EU5 Market Access Opportunities and Barriers for Outpatient Parenteral Antibiotic Therapy| Physician & Payer Forum | EU5 | 2015

Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do not otherwise require hospitalization. In addition to improved convenience, OPAT offers distinct advantages over inpatient treatment, such as the potential to reduce healthcare costs and decrease the risk of complications due to prolonged hospitalization. Nonetheless, in contrast to its widespread use in the United States, the OPAT treatment modality has been slower to gain traction in the EU5. However, given that the reduction of treatment costs associated with inpatient antibiotic therapy can be a key driver of OPAT prescribing, commercial opportunity exists for novel antibiotics that can increase OPAT use via improvements in efficacy, safety, and delivery over currently available parenteral drugs.

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…